Introduction The Indian Pharmaceutical Industry is at the forefront of India's science-based industries. It is a highly organized industry. The industry is estimated to be worth $4.5 billion, with annual growth of between 8 and 9 percent. It ranks very high in terms of technology, quality and range of medicines produced. From simple headache pills to heavy antibiotics and complex cardiac compounds, almost every type of medicine is now produced locally. It meets around 70% of the country's demand for bulk drugs, pharmaceutical intermediates, tablets, chemicals, capsules, oral and injectable pharmaceutical formulations. There are 250 large scale units and 8,000 small scale units, which form the core of the Indian pharmaceutical industry (including 5 central public sector units). Indian pharmaceutical industry in 2012 – 2014 Increase in sales of generic drugs, growth of chronic therapies and greater penetration into rural markets are the reasons for double-digit growth, equal to 13-14% in 2013. 2012 ended with a growth of 12%. It attracted FDI worth $9,776 million between April 2000 and November 2012. India's exports of drugs and pharmaceutical products grew 27% to Rs 60,000 crore ($11.19 billion) for the year ended March 2012. This industry is expected to show double-digit growth in the future due to increasing pharmaceutical outsourcing and increasing investments by multinational companies. Most companies in this sector have shown a notable decline in growth in the first half of 2011. Companies like Cipla, Torrent and IPCA that have focused on the Indian market are already in trouble. The growth rates of companies like Dr. Reddy and Ranbaxy have declined. On the other hand Sun and Lupine are showing growth due to the shift of...... middle of the card....... Return on equity in 2010 was 18.31% to 16.99% in 2013. The dividend payout ratio was maximum in 2011 of 27.23%. The debt-to-equity ratio remained very low, i.e. 0.11, which is much lower than the ideal ratio of 2:1. EPS increased from Rs. 9.99 in 2009 to around Rs 18.77 in 2013 with gradual increase over the course. The DPS for two years remained constant from 2009 to 2013 at Rs. 2. Book value per share EPS has remained almost the same i.e. from around Rs. 5.99 in 2009 became Rs. 5.88 in the year 2013.(http://www.moneycontrol.com/news/business/indias-pharma-industry-seeing-rapid-growth-wockhardt_1013349.html)CONCLUSION: From the above table and interpretation it can be concluded that CIPLA has a decent performance as the dividend payment is constant and the EPS is increasing. Therefore, investing in this company could be a good option.